Veritas Pharma Stock Revenue
| VRTHF Stock | USD 0 0.00 0.00% |
Veritas Pharma fundamentals help investors to digest information that contributes to Veritas Pharma's financial success or failures. It also enables traders to predict the movement of Veritas Pink Sheet. The fundamental analysis module provides a way to measure Veritas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Veritas Pharma pink sheet.
Veritas |
Veritas Pharma Company Revenue Analysis
Veritas Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Veritas Pharma reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Veritas Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veritas Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Veritas Pharma could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics of similar companies.Veritas Pharma is currently under evaluation in revenue category among its peers.
Veritas Fundamentals
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Shares Owned By Insiders | 27.34 % | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| Gross Profit | (112.96 K) | |||
| EBITDA | (491.67 K) | |||
| Net Income | (2.29 M) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.64 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Beta | -0.0588 | |||
| Market Capitalization | 1.59 M | |||
| Total Asset | 730 | |||
| Net Asset | 730 |
About Veritas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veritas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veritas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veritas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Veritas Pink Sheet
Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.